Short Courses*


SUNDAY, APRIL 30
MORNING 10:00 am - 1:00 pm

SC1: Preclinical and Clinical Immunogenicity Bioanalysis: ADCs, Multi-Domain Biotherapeutics and New Modalities - View Detailed Agenda

Darshana Jani, M.S., Senior Manager, Pfizer, Inc.

Priya Sriraman, Ph.D., Principal Investigator, Biotherapeutics Development, Celgene Corp

Seema Kumar, Ph.D., Associate Director, EMD Serono

Corinna Krinos Fiorotti, Ph.D., Business Development Manager, Bioagilytix

SC2: Translational Considerations for Development of Monoclonal Antibodies Part I: Focus on Early Discovery - View Detailed Agenda

Gadi Bornstein, Ph.D., Global Correlative Science Leader, Director, Novartis Pharmaceuticals
Enrique Escandon Ph.D., Senior Principal Scientist, DMPK and Disposition, Merck Research Laboratories
Vaishnavi Ganti, Ph.D., Associate Principal Scientist, Biologics Discovery-DMPK, Merck Research Laboratories
Veronica Juan, Ph.D., Principal Scientist, Protein Sciences, Merck Research Labs

Scott L. Klakamp, Ph.D., Principal, SKD Consulting LLC

Mohammad Tabrizi, Ph.D., Director Biologics Discovery, Merck Research Laboratories

SC3: Genomics in the Service of Cancer Immunotherapy - View Detailed Agenda

Zoltan Szallasi, Ph.D., M.D., Senior Research Scientist, Informatics Program; Assistant Professor, Pediatrics, Children’s Hospital Boston and Harvard Medical School

SC4: The Multi-Attribute Method (MAM) for Improving Product and Process Development - View Detailed Agenda

Richard Rogers, Ph.D., Scientist 4, Just Biotherapeutics

SC6: In silico Protein Docking - View Detailed Agenda

Vinodh B. Kurella, Ph.D., Senior Scientist, Molecular Engineering Unit, Intexon Corp.

 

AFTERNOON 2:00 - 5:00 pm

SC7: Translational Considerations for Development of Monoclonal Antibodies Part II: Focus on Nonclinical Development to the Clinic - View Detailed Agenda

Gadi Bornstein, Ph.D., Global Correlative Science Leader, Director, Novartis Pharmaceuticals
Enrique Escandon Ph.D., Senior Principal Scientist, DMPK and Disposition, Merck Research Laboratories
Vaishnavi Ganti, Ph.D., Associate Principal Scientist, Biologics Discovery-DMPK, Merck Research Laboratories
Veronica Juan, Ph.D., Principal Scientist, Protein Sciences, Merck Research Labs

Scott L. Klakamp, Ph.D., Principal, SKD Consulting LLC

Mohammad Tabrizi, Ph.D., Director Biologics Discovery, Merck Research Laboratories

SC8: In silico Immunogenicity Predictions – A Hands-On Workshop - View Detailed Agenda

Vinodh B. Kurella, Ph.D., Senior Scientist, Molecular Engineering Unit, Intrexon Corp.

Paolo Marcatili, Ph.D., Asst. Professor, Bio and Health Informatics Department, Technical University of Denmark

SC9: Target Selection for Biologics - View Detailed Agenda

William R. Strohl, Ph.D., President, BiStro Biotech Consulting, LLC

SC11: Adoptive Therapy with CAR T Cells - View Detailed Agenda

Prasad S. Adusumilli, M.D., F.A.C.S., Associate Attending and Deputy Chief, Thoracic Surgery, Memorial Sloan Kettering Cancer Center

Carl J DeSelm, M.D., Ph.D., Researcher, Immunotherapy, Memorial Sloan Kettering Cancer Center

Matthew J. Frigault, M.D., Clinical Fellow in Medicine, Dana-Farber Cancer Institute

Eric L. Smith, M.D., Ph.D., Assistant Attending, Myeloma Service; Director of Clinical Translation, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center

 

TUESDAY, MAY 2
DINNER 6:00 - 8:30 pm

SC12: Study Design and Statistical Data Analysis of Flow Cytometry Assays - View Detailed Agenda

Shuguang Huang, Ph.D., CSO, Stat4ward LLC

SC13: Phenotypic Screening Applications and Technologies - View Detailed Agenda

Steven Rust, Ph.D., Senior Manager, R&D, MedImmune

SC14: Overcoming the Challenges of Immunogenicity Assays, Risk Assessment and Regulatory Requirements - View Detailed Agenda

Jim McNally, Ph.D., Associate Director and Immunogenicity Expert, Global Early Development - Quantitative Pharmacology & Drug Disposition, EMD Serono
Bonnie Rup, Ph.D., Independent Consultant


DINNER 6:00 - 9:00 pm

SC17: Transient Protein Production in Mammalian Cells - View Detailed Agenda

Richard Altman, MS, Scientist, Protein Technologies, Amgen
Henry C. Chiou, Ph.D., Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc.
Panelist: Barry A. Morse, Ph.D., Principal Research Scientist, Biologics Research, Janssen Research and Development


THURSDAY, MAY 4
DINNER 5:45 - 8:15 pm

SC15: Critical Considerations for the Design and Development of Antibody-Drug Conjugates - View Detailed Agenda

Isabel Figueroa, Ph.D., Scientist, PTPK, Genentech, Inc.
Shawn Owen, Ph.D., Assistant Professor, Pharmaceutics and Pharmaceutical Chemistry; and Adjunct Professor, Internal Medicine, University of Utah

SC16: New USP Initiatives for Characterization and Release of Biologics - View Detailed Agenda

Maura C. Kibbey, Ph.D., Director Science & Standards, Global Biologics, US Pharmacopeia
Steven L. Walfish, Ph.D., Principal Science & Standards Liaison, US Pharmacopeia

SC18: Clinical Prospects of Cancer Immunotherapy - View Detailed Agenda

Gaurav Goel, M.D., Assistant Professor, Division of Medical Oncology, Medicine, University of Kentucky Markey Cancer Center

SC19: Strategic Bioassay Design and Analysis - View Detailed Agenda

Liming Shi, MS, MA, Senior Group Leader, Bioassay Development, Hospira, a Pfizer Company


*Separate Registration Required


Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag


View By: